Last reviewed · How we verify
Clindamycin Gel
Clindamycin Gel, marketed by Lee's Pharmaceutical Limited, holds a position in the topical antibiotic segment with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and mechanism of action, which addresses bacterial skin infections effectively. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Clindamycin Gel |
|---|---|
| Also known as | Clindamycin |
| Sponsor | Lee's Pharmaceutical Limited |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel) (NA)
- Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris (PHASE4)
- Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Therapeutic Management of Periodontitis and Clinical Manifestations of Rheumatoid Arthritis (NA)
- Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel (PHASE2)
- Effect of Intracanal Medicaments on Post-Operative Pain in Symptomatic Apical Periodontitis: An RCT (NA)
- Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clindamycin Gel CI brief — competitive landscape report
- Clindamycin Gel updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI